These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21071324)

  • 21. Exploring knowledge of prescription charges: a cross-sectional survey of pharmacists and the community.
    Willmot EJ; Lawton BA; Rose SB; Brown S
    N Z Med J; 2009 Aug; 122(1301):19-24. PubMed ID: 19829388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discounted drug prices for hospitals: result in prescriptions for expensive drugs in the community.
    Prescrire Int; 2015 Sep; 24(163):223. PubMed ID: 26417639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Competition between branded and generic drugs in Austria: evidence from the market for ACE inhibitors].
    Mahlich JC; Stadler I
    Gesundheitswesen; 2012 Jan; 74(1):23-8. PubMed ID: 21154203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Building a business case for an outpatient pharmacy.
    Burger GS; Jorgenson JA; Stevenson JG
    Healthc Financ Manage; 2015 Jun; 69(6):76-81. PubMed ID: 26665338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Services provided by community pharmacies in Wayne County, Michigan: a comparison by ZIP code characteristics.
    Erickson SR; Workman P
    J Am Pharm Assoc (2003); 2014; 54(6):618-24. PubMed ID: 25379982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Policies concerning pharmaceutical prices and reimbursement in Mexico, Organization for Co-operation and Economic Development. 2007].
    Moïse P; Docteur E
    Salud Publica Mex; 2008; 50 Suppl 4():S504-10. PubMed ID: 19082262
    [No Abstract]   [Full Text] [Related]  

  • 28. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The GO License: only part of the solution.
    Batson A; Milstien JB
    Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addressing the Lack of Competition in Generic Drugs to Improve Healthcare Quality and Safety.
    Sivashanker K; Fanikos J; Kachalia A
    J Gen Intern Med; 2018 Nov; 33(11):2005-2007. PubMed ID: 30091120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of generic competition on prescription to over-the-counter switching.
    Hollenbeak CS
    Pharmacoeconomics; 1999 Dec; 16(6):661-8. PubMed ID: 10724793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PBMs' rebate income threatened by lawsuits and move to generics.
    Sipkoff M
    Manag Care; 2008 Mar; 17(3):11-2. PubMed ID: 18447152
    [No Abstract]   [Full Text] [Related]  

  • 34. Could a Wal-Mart PBM succeed?
    Carroll J
    Manag Care; 2008 Apr; 17(4):36-8. PubMed ID: 18464572
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacies receiving massive rebates from generic drug-makers.
    Silversides A
    CMAJ; 2006 Aug; 175(4):342. PubMed ID: 16908889
    [No Abstract]   [Full Text] [Related]  

  • 36. Another war on drugs. European countries turn to 'reference pricing' in battle against soaring cost of pharmaceuticals.
    Hensley S
    Mod Healthc; 1999 Nov; 29(46):38-9. PubMed ID: 10662043
    [No Abstract]   [Full Text] [Related]  

  • 37. Indian generics companies go on spending spree.
    Jayaraman KS
    Nat Rev Drug Discov; 2005 Aug; 4(8):616-7. PubMed ID: 16106583
    [No Abstract]   [Full Text] [Related]  

  • 38. Price and welfare effects of a pharmaceutical substitution reform.
    Granlund D
    J Health Econ; 2010 Dec; 29(6):856-65. PubMed ID: 20832130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Don't pay too much for generic fills. Pass-through pricing is a good way for a payer to realize the benefit of increased prescribing of generic drugs.
    Cahn LJ
    Manag Care; 2010 Nov; 19(11):21-7. PubMed ID: 21141372
    [No Abstract]   [Full Text] [Related]  

  • 40. Competition authority will investigate price hikes of generic drugs.
    Hawkes N
    BMJ; 2016 Nov; 355():i5849. PubMed ID: 27802935
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.